Labetuzumab

Names

[ CAS No. ]:
219649-07-7

[ Name ]:
Labetuzumab

Biological Activity

[Description]:

Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[Target]

CEA[1].

[In Vivo]

Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1]. Animal Model: Female nu/nu mice (6 to 8-week-old; inject TT cells)[1]. Dosage: 0.5 mg/rat Administration: Intravenous injection; single (1 day post-tumor cell injection) Result: Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.

[References]

[1]. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3(12):1559-64.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.